There is a particular frustration that equity investors know well, and that London’s institutional community was forced to revisit on Wednesday morning: the earnings beat that the market still sells. AstraZeneca reported Q1 revenue of $15.3 billion, up 8% at constant exchange rates, driven by double-digit growth in oncology and rare disease — a result that CEO Pascal Soriot called “strong growth” demonstrating “consistent commercial execution.” The stock fell 1.4%. Lloyds Banking Group reported a better-than-expected rise in first-quarter profit, slightly upgraded its net interest income guidance, and reiterated its full-year targets. The stock dipped 1.4% before recovering to near-flat. GSK beat earnings expectations. Its shares fell 2.1%.
By 09:50 GMT on Wednesday, the FTSE 100 had slipped 0.7% — its seventh decline in eight sessions. The FTSE 250 eased a more modest 0.1%. The morning’s corporate results, which included AstraZeneca, GSK, Lloyds, Haleon, Jet2, Aston Martin, Melrose, and Halfords across both indices, were by any objective financial standard a respectable mixed bag. But the market that greeted them was not in the business of rewarding good results on Wednesday. It was in the business of managing risk ahead of two of the most consequential central bank decisions of the year: the Federal Reserve’s meeting — Jerome Powell’s last before stepping down — and the Bank of England’s rate decision on Thursday.
The result was a morning where companies beat estimates and their shares fell anyway, where a private equity bid generated the session’s biggest winner, and where the market’s dominant preoccupation remained the question that has been driving every investment decision since February 28: what happens in the Strait of Hormuz next.
AstraZeneca: A Quarter That Deserved More
AstraZeneca’s Q1 2026 results were, by the standards of any large-cap pharmaceutical company, strong. Total revenue of $15.3 billion, up 8% at constant exchange rates, was driven by what Soriot described as the company’s “catalyst-rich period” — four positive readouts from Phase III programmes since the company’s last quarterly results, including first pivotal data for tozorakimab in COPD and efzimfotase alfa in hypophosphatasia. Oncology and rare disease, the two divisions that have driven AstraZeneca’s transformation from a mid-tier European pharma into the FTSE 100’s second-largest company, both delivered double-digit growth. The company reiterated its full-year guidance for revenue to increase by a mid-to-high single-digit percentage at constant exchange rates, with core EPS forecast to grow by a low double-digit percentage.
None of this was sufficient to prevent a 1.4% decline on Wednesday. The explanation is a familiar one in the current market environment: investors who have already priced in execution and are now demanding evidence that the guidance is conservative enough to be beaten. AstraZeneca’s full-year guidance reiteration, rather than an upgrade, was read by some participants as an indication that management sees the current external environment — Iran war supply chain disruptions, currency headwinds from the strong dollar against sterling, and Chinese oncology market pricing pressure — as meaningful enough to limit its upgrading ambitions for now.
GSK, the other major British pharmaceutical company reporting on Wednesday, told a similar story. Better-than-expected quarterly results were paired with a full-year guidance reaffirmation rather than a raise, and the stock fell 2.1%. Haleon, the consumer health joint venture that was spun out of GSK in 2022 and carries brands including Sensodyne, Panadol, and Voltaren, fell 2.1% on its own results. St James’s Place dropped 5.75% after reporting first-quarter funds under management of £217 billion — below market expectations of £219 billion — despite net inflows of £1.53 billion that beat the consensus. Downward market movements of £4.6 billion in the quarter, driven by the geopolitical and market volatility of February and March, overwhelmed the positive flows.
Lloyds: A Provision That Speaks Louder Than the Beat
Lloyds Banking Group’s Q1 results were better than expected on the headline measures that usually drive the share price. Net interest income of £3.57 billion came in above the consensus estimate of £3.55 billion. The bank slightly upgraded its full-year net interest income guidance to “exceeding £14.9 billion” from “around £14.9 billion.” It maintained its target for return on tangible equity of more than 16% and operating costs below £9.9 billion. CEO Charlie Nunn said: “We are confident in our delivery for the year ahead and reiterate our guidance for 2026.”
What arrested the natural reaction to those numbers was a specific disclosure buried deeper in the Q1 management statement: a £295 million provision in the quarter that included money set aside to cover potential bad loans, reflecting an update to Lloyds’ economic models to adopt “a more cautious view on this year’s growth.” That phrase — “more cautious view on this year’s growth” — is the language of a bank that has looked at the Iran war’s impact on the UK economy and concluded that its loan book faces a higher probability of stress than it did three months ago.
The OECD’s assessment provides context for Lloyds’ caution: among G7 countries, the UK is expected to be the worst affected by events in the Middle East. The United Kingdom’s economic exposure to the Iran war runs through multiple channels — energy costs affecting households and businesses, the disruption to global trade flows passing through UK ports, and the dampening of business investment and consumer confidence that a sustained geopolitical shock typically produces. Lloyds, as the UK’s largest domestic retail and commercial lender with £496.5 billion in deposits and £481.5 billion in loans, carries the most concentrated exposure to UK economic health of any major bank in the country.
The provision was prudent. It was also an admission that the macro backdrop has materially deteriorated, and that admission — more than the NII beat — is what the market focused on. Lloyds shares dipped 1.4% before recovering to near-flat, reflecting the tension between a strong quarter and a cautious forward-looking signal.
DCC: The Day’s Standout Winner
If Wednesday’s theme was “beat the estimates, lose the share price,” DCC plc was the exception that proved the rule. The Irish energy and technology distribution group — the fourth FTSE 100 company this year to attract a takeover approach — confirmed it has received an indicative all-cash bid from a consortium of US private equity firms Energy Capital Partners and KKR. The DCC board has until June 10, 2026 to announce whether the consortium has made a firm offer or withdrawn. Shares jumped more than 14% on the news.
The DCC bid sits in the broader context of an extraordinary year for FTSE 100 M&A. The total value of takeover bids tabled for listed UK companies has already reached £29.7 billion in 2026 — significantly higher than at the equivalent point in any of the previous five years. The average premium on all 2026 deals is approximately 39%. AJ Bell investment director Russ Mould noted that the DCC approach “suggests that the UK equity market continues to offer value, judging by how prospective trade and financial buyers from home and abroad seem keen to snap up London-listed companies.”
That observation carries strategic weight. Foreign and private equity buyers paying 39% premiums for UK-listed assets are, in effect, expressing a view that the London market persistently undervalues the companies listed on it. In DCC’s specific case, the buyers are acquiring exposure to energy distribution infrastructure at a moment when “energy security and its importance in the context of both industrial supply chains and also national security” has become one of the highest-priority investment themes in the world — a direct consequence of the disruption caused by the Iran war, Russia’s attack on Ukraine, and the supply chain vulnerabilities exposed by both.
The Backdrop: Two Central Banks, One Impasse
The market’s reluctance to reward even strong results on Wednesday reflects the dominance of two macro variables that earnings results cannot resolve.
The first is the Iran war itself. Efforts to end the conflict remain at an impasse, with President Trump reportedly unhappy with Tehran’s latest negotiating proposal because it does not address nuclear issues from the outset. Brent crude oil was rising toward $111 per barrel on Wednesday, following a more than 2.8% gain on Tuesday that took WTI above $99. Oil at these levels is an inflation story, a margin story, and a consumer confidence story simultaneously. The FTSE 100’s seven declines in eight sessions have occurred against a backdrop of oil at or approaching $100 — a level that changes the financial equations of virtually every listed company.
The second is the central bank calendar. Wednesday is the Federal Reserve’s meeting — Jerome Powell’s last as chair before he steps down — with markets pricing a 78% probability of no rate change, according to CME FedWatch. Powell’s comments on oil-driven inflation and the Fed’s outlook for the rest of the year will be parsed more closely than the rate decision itself. On Thursday, the Bank of England meets on its own rate decision, with UK market makers watching for any signal that the energy shock is shifting the MPC’s calculus on the pace of easing.
In that context, the earnings results of Wednesday morning — however respectable — were always going to be secondary characters in a market narrative still dominated by oil prices, peace talks, and what the world’s two most important central bankers choose to say about both.
The FTSE 100 fell seven times in eight sessions. The companies whose results drove that session largely beat expectations. The market sold them anyway — and that tells you more about the current investment environment than any individual earnings number can.
Written by Shalin Soni, CMA specializing in financial analysis, global markets, and corporate strategy, with hands-on experience in financial planning and analytical decision-making.
ALSO READ
• OpenAI Trial Begins as Elon Musk and Sam Altman Clash Over AI’s Future
• India’s Digital Rupee Targets Welfare Leakages in Major Subsidy Overhaul
• Best Buy Taps Veteran Bonfig to Lead Turnaround Amid Weak Consumer Demand
Source: Based on Reuters and publicly available financial information.